Germany's CureVac to launch human trial of experimental coronavirus vaccine
Coronavirus chronicle
17 June, 2020, 03:35 pm
Last modified: 17 June, 2020, 03:39 pm
It was reported that Paul Ehrlich Institut would approve testing on humans of the experimental vaccine
Representational Image. Photo: Reuters
Unlisted German biotech firm CureVac will become the second company to launch human trials of an experimental coronavirus vaccine in the country, Germany's vaccines regulator said on Wednesday.
Reuters reported on Tuesday that the watchdog, the Paul Ehrlich Institut, would approve testing on humans of the experimental vaccine.
Comments
While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.